CUL3 and neoplasm: The progression‐free survival (PFS) analysis, which can better reflect tumor progression and predict clinical benefits, also showed an association between KEAP1/NFE2L2/CUL3 mutation and faster disease progression (median survival time: 17.7 months vs. 31.7 months, p = 0.016).